Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Cancer of unknown primary origin

ESMO 2010

Published: 1 Nov 2010

Views: 6759

Rating:

Save

Prof Nicholas Pavlidis - University of Ioannina, Greece

Prof Nicholas Pavlidis speaks about the effects, prevalence and best ways of detecting and treating cancer of unknown primary origin (CUP). Prof Pavlidis stresses the importance of a correct diagnosis and explains the differences in treatment for CUP depending on the patient’s prognosis.

Categories:
Diagnostics

Related Videos

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Tele-mentoring: Impact of project ECHO

Dr Sanjeev Arora - Project ECHO, Albuquerque, USA

Tele-mentoring: Impact of project ECHO ( Dr Sanjeev Arora - Project ECHO, Albuquerque, USA )

Predicting tumour mutations from pathology images may help increase...

Dr Rom Leidner - Providence Cancer Institute, Portland, USA

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )

Choosing the right patients for transplant

Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India

Choosing the right patients for transplant ( Dr Sameer Tulpule - Kokilaben Dhirubhai Ambani Hospital, Mumbai, India )

Choosing Wisely in endometrial & cervix cancers: Medical therapy

Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India

Choosing Wisely in endometrial & cervix cancers: Medical therapy ( Dr Jaya Ghosh - Tata Memorial Hospital, Mumbai, India )

Cancer mutation prediction using artificial intelligence

Dr Carlo Bifulco - Providence Cancer Institute, Southfield, USA

Cancer mutation prediction using artificial intelligence ( Dr Carlo Bifulco - Providence Cancer Institute, Southfield, USA )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Understanding patient factors and barriers in oncology treatment

Dr Prateek Jain - Tata Medical Center, Kolkata

Understanding patient factors and barriers in oncology treatment ( Dr Prateek Jain - Tata Medical Center, Kolkata )

Hormonal receptor positive breast cancer adjuvant and metastatic indications

Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA

Hormonal receptor positive breast cancer adjuvant and metastatic indications ( Dr Aurelio Castrellon - Memorial Cancer Institute, Miami, USA )

More from ecancer